Related Experiment Video
Updated: Mar 9, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
[IgA nephropathy - prognostic factors and treatment]
Monika Wieliczko1, Magdalena Dylewska2
1Katedra i Klinika Nefrologii, Dializoterapii i Chorób Wewnętrznych WUM, Warszawa, Polska, monfeb@wp.pl.
IgA nephropathy, a common kidney disease, has varying progression risks. Management includes therapies to slow kidney damage and, for some, immunosuppression.
Area of Science:
- Nephrology
- Immunology
Background:
- Immunoglobulin A (IgA) nephropathy is the leading cause of primary glomerulonephritis.
- Disease progression varies significantly among patients.
- Risk stratification is crucial for patient management.
Purpose of the Study:
- To summarize the current understanding of IgA nephropathy.
- To outline the diagnostic criteria and prognostic factors.
- To review current and emerging therapeutic strategies.
Main Methods:
- Literature review of IgA nephropathy studies.
- Analysis of clinical presentation and laboratory findings.
- Evaluation of treatment outcomes for nephroprotective and immunosuppressive therapies.
Main Results:
- Patients with isolated hematuria and minimal proteinuria (<0.5 g/d) with normal renal function typically have a low risk of progression.
- Elevated proteinuria and/or serum creatinine indicate a higher risk of progression to end-stage renal disease.
- Renin-angiotensin-aldosterone system (RAAS) blockade is a cornerstone nephroprotective therapy.
Conclusions:
- IgA nephropathy management requires individualized approaches based on risk factors.
- RAAS blockade is essential for slowing disease progression.
- Immunosuppressive therapy may benefit select patient groups.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Acute Kidney Injury III: Clinical Manifestations

